<DOC>
	<DOCNO>NCT01728285</DOCNO>
	<brief_summary>Adherence treatment crucial efficacy sublingual immunotherapy allergic disease . GRAZAX® register drug Europe , establish efficacy treatment allergic rhinitis , take daily patient . This study aim establish device characteristic mechanical dispenser ( Memozax® ) could improve adherence treatment subject hay fever due allergy grass</brief_summary>
	<brief_title>Compliance Treatment With GRAZAX® Tablets Patients With Seasonal Grass Pollen Rhinoconjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>A clinical history grass polleninduced allergic rhinoconjunctivitis ( without asthma ) receive treatment previous grass pollen season . Positive skin prick test ( SPT ) response ( wheal diameter ≥3mm ) Phleum pratense Positive specific IgE Phleum pratense ( IgE titer &gt; class 2 ) Clinical history chronic sinusitis last 2 year symptomatic perennial seasonal allergic rhinitis and/or asthma receive regular medication , due another allergen potentially overlap grass pollen season . Clinical history severe asthma ( GINA Step 4 child Forced Expiratory Volume 1 second ( FEV1 ) &lt; 80 % expect value treatment inhaled corticosteroid shortacting β2 agonist ) Previous treatment immunotherapy grass pollen allergen allergen within previous 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>specific allergen immunotherapy</keyword>
	<keyword>sublingual immunotherapy</keyword>
	<keyword>allergen tablet</keyword>
	<keyword>compliance</keyword>
	<keyword>electronic compliance device</keyword>
</DOC>